HR-8630-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Michael Rulli (R-OH)
What it does
This bill would amend the Public Health Service Act to prohibit the FDA from classifying a biologic as a "biological product" solely because it contains a protein that is a clinically inactive component. In practice, this would affect desiccated thyroid extract (DTE) medications — natural thyroid drugs derived from animal glands that contain both active thyroid hormones and inactive proteins. Under current law, the presence of those proteins could subject DTE products to the more stringent and costly regulatory pathway required for biological products.
Who benefits
Patients who use desiccated thyroid extract (DTE) medications such as Armour Thyroid or NP Thyroid to treat hypothyroidism — estimated at hundreds of thousands of Americans. Manufacturers and compounding pharmacies that produce DTE products, who would avoid the more burdensome biologics approval process. Physicians who prescribe DTE as an alternative to synthetic levothyroxine. Patients who have not responded well to synthetic thyroid hormone and rely on DTE as their primary treatment option.
Who is hurt
Manufacturers of synthetic thyroid hormone drugs (e.g., levothyroxine/Synthroid) who could face increased competition if DTE products remain more accessible. Patients and advocacy groups who argue that stricter biologics oversight provides stronger safety and consistency guarantees. The FDA, which would lose regulatory flexibility to classify DTE products as biologics based on their protein content. Potentially, patients who might benefit from the more rigorous safety and efficacy standards applied to biological products.
Supporters argue
Supporters argue that desiccated thyroid extract has been used safely to treat hypothyroidism for over a century and that applying the biologics regulatory pathway to DTE — solely because of clinically inactive proteins — would impose unnecessary costs and barriers that could remove a proven treatment option from the market. They contend that for a meaningful subset of hypothyroid patients, DTE produces better clinical outcomes than synthetic levothyroxine, and that restricting access based on a regulatory technicality rather than clinical evidence harms those patients without a corresponding safety benefit.
Opponents argue
Opponents argue that the biologics regulatory framework exists precisely to ensure rigorous safety and consistency standards for complex, protein-containing drugs, and that carving out DTE based on the "clinical inactivity" of its proteins sets a potentially broad precedent for weakening oversight of other biologic-adjacent products. They contend that the determination of which proteins are "clinically inactive" is itself a scientific judgment that should remain with the FDA rather than be resolved by statute, and that removing this classification authority could create regulatory gaps that compromise patient safety and drug consistency standards.
Constitutional context
Congress has broad authority to regulate drug manufacturing and approval under the Commerce Clause (Art. I, §8, cl. 3), as pharmaceutical products move in interstate commerce. No significant constitutional tension is present; this bill modifies an existing statutory definition rather than raising enumerated powers questions. Post-Loper Bright (2024), however, courts would independently review any FDA interpretation of the amended statutory language rather than deferring to the agency.
Checks and balances
Congress would narrow FDA's classification authority by statute; the FDA retains enforcement and approval authority over DTE products through other regulatory pathways, and courts would independently review any agency interpretation of the new statutory language under Loper Bright.
Historical precedent
Congress has previously carved out specific drug categories from regulatory pathways, such as the exemption for compounded drugs under the Drug Quality and Security Act (2013), though no prior legislation has directly addressed the biologics classification of desiccated thyroid extract.